Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

VEGF Receptor Inhibitors Block the Ability of Metronomically Dosed Cyclophosphamide to Activate Innate Immunity–Induced Tumor Regression
Joshua C. Doloff, David J. Waxman
Cancer Research (2012) Vol. 72, Iss. 5, pp. 1103-1115
Open Access | Times Cited: 88

Showing 1-25 of 88 citing articles:

Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer
Laura Bracci, Giovanna Schiavoni, Antonella Sistigu, et al.
Cell Death and Differentiation (2013) Vol. 21, Iss. 1, pp. 15-25
Open Access | Times Cited: 840
Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy
Junjie Wu, David J. Waxman
Cancer Letters (2018) Vol. 419, pp. 210-221
Open Access | Times Cited: 291
Metronomic chemotherapy: An attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance
Irina Kareva, David J. Waxman, Giannoula Klement
Cancer Letters (2014) Vol. 358, Iss. 2, pp. 100-106
Open Access | Times Cited: 219
Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect
Guido Bocci, Robert S. Kerbel
Nature Reviews Clinical Oncology (2016) Vol. 13, Iss. 11, pp. 659-673
Closed Access | Times Cited: 183
A Think Tank of TINK/TANKs: Tumor-Infiltrating/Tumor-Associated Natural Killer Cells in Tumor Progression and Angiogenesis
Antonino Bruno, Guido Ferlazzo, Adriana Albini, et al.
JNCI Journal of the National Cancer Institute (2014) Vol. 106, Iss. 8, pp. 1-13
Open Access | Times Cited: 169
The contribution of tumor-associated macrophages in glioma neo-angiogenesis and implications for anti-angiogenic strategies
Changbin Zhu, Johan M. Kros, Caroline Cheng, et al.
Neuro-Oncology (2017) Vol. 19, Iss. 11, pp. 1435-1446
Open Access | Times Cited: 148
The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma
Minghui Li, Aaron Bolduc, Md Nasrul Hoda, et al.
Journal for ImmunoTherapy of Cancer (2014) Vol. 2, Iss. 1, pp. 21-21
Open Access | Times Cited: 137
The microvascular niche instructs T cells in large vessel vasculitis via the VEGF-Jagged1-Notch pathway
Zhenke Wen, Yi Shen, Gerald J. Berry, et al.
Science Translational Medicine (2017) Vol. 9, Iss. 399
Open Access | Times Cited: 113
Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8+T-cell responses and immune memory
Junjie Wu, David J. Waxman
OncoImmunology (2015) Vol. 4, Iss. 4, pp. e1005521-e1005521
Open Access | Times Cited: 95
Chemotherapeutic drug-induced immunogenic cell death for nanomedicine-based cancer chemo–immunotherapy
Mingxia Jiang, Jun Zeng, Liping Zhao, et al.
Nanoscale (2021) Vol. 13, Iss. 41, pp. 17218-17235
Closed Access | Times Cited: 94
Multifunctional Lipid Bilayer Nanocarriers for Cancer Immunotherapy in Heterogeneous Tumor Microenvironments, Combining Immunogenic Cell Death Stimuli with Immune Modulatory Drugs
André E. Nel, Kuo‐Ching Mei, Yu‐Pei Liao, et al.
ACS Nano (2022) Vol. 16, Iss. 4, pp. 5184-5232
Open Access | Times Cited: 45
Metronomic chemotherapy and drug repurposing: A paradigm shift in oncology
Nusrat Jan, Shazia Sofi, Hina Qayoom, et al.
Heliyon (2024) Vol. 10, Iss. 3, pp. e24670-e24670
Open Access | Times Cited: 15
Immune Response to Cancer Therapy: Mounting an Effective Antitumor Response and Mechanisms of Resistance
Terry R. Medler, Tiziana Cotechini, Lisa M. Coussens
Trends in cancer (2015) Vol. 1, Iss. 1, pp. 66-75
Open Access | Times Cited: 86
Oncolytic viruses as immunotherapy: progress and remaining challenges
Laure Aurelian
OncoTargets and Therapy (2016), pp. 2627-2627
Open Access | Times Cited: 83
Metronomic reloaded: Theoretical models bringing chemotherapy into the era of precision medicine
Sébastien Benzekry, Eddy Pasquier, Dominique Barbolosi, et al.
Seminars in Cancer Biology (2015) Vol. 35, pp. 53-61
Open Access | Times Cited: 80
Cancer-Induced Alterations of NK-Mediated Target Recognition: Current and Investigational Pharmacological Strategies Aiming at Restoring NK-Mediated Anti-Tumor Activity
Anne-Sophie Chrétien, Aude Le Roy, Norbert Vey, et al.
Frontiers in Immunology (2014) Vol. 5
Open Access | Times Cited: 76
Medium dose intermittent cyclophosphamide induces immunogenic cell death and cancer cell autonomous type I interferon production in glioma models
Bin Du, David J. Waxman
Cancer Letters (2019) Vol. 470, pp. 170-180
Open Access | Times Cited: 68
Intermittent Metronomic Drug Schedule Is Essential for Activating Antitumor Innate Immunity and Tumor Xenograft Regression
Chong-Sheng Chen, Joshua C. Doloff, David J. Waxman
Neoplasia (2014) Vol. 16, Iss. 1, pp. 84-W27
Open Access | Times Cited: 67
The potential clinical promise of ‘multimodality’ metronomic chemotherapy revealed by preclinical studies of metastatic disease
Robert S. Kerbel, Yuval Shaked
Cancer Letters (2017) Vol. 400, pp. 293-304
Closed Access | Times Cited: 66
Diffuse optical spectroscopic imaging reveals distinct early breast tumor hemodynamic responses to metronomic and maximum tolerated dose regimens
Anup Tank, Hannah Peterson, Vivian Pera, et al.
Breast Cancer Research (2020) Vol. 22, Iss. 1
Open Access | Times Cited: 65
A Combination of Immune Checkpoint Inhibition with Metronomic Chemotherapy as a Way of Targeting Therapy-Resistant Cancer Cells
Irina Kareva
International Journal of Molecular Sciences (2017) Vol. 18, Iss. 10, pp. 2134-2134
Open Access | Times Cited: 64
Low-dose metronomic chemotherapy: from past experience to new paradigms in the treatment of cancer
David Loven, Erez Hasnis, Francesco Bertolini, et al.
Drug Discovery Today (2012) Vol. 18, Iss. 3-4, pp. 193-201
Closed Access | Times Cited: 72
Anti-Bv8 Antibody and Metronomic Gemcitabine Improve Pancreatic Adenocarcinoma Treatment Outcome Following Weekly Gemcitabine Therapy
Erez Hasnis, Dror Alishekevitz, Svetlana Gingis-Veltski, et al.
Neoplasia (2014) Vol. 16, Iss. 6, pp. 501-510
Open Access | Times Cited: 61
Metronomic cyclophosphamide schedule-dependence of innate immune cell recruitment and tumor regression in an implanted glioma model
Junjie Wu, David J. Waxman
Cancer Letters (2014) Vol. 353, Iss. 2, pp. 272-280
Open Access | Times Cited: 57
Evidence Implicating Immunological Host Effects in the Efficacy of Metronomic Low-Dose Chemotherapy
Yuval Shaked, Elizabeth Pham, Santosh Hariharan, et al.
Cancer Research (2016) Vol. 76, Iss. 20, pp. 5983-5993
Open Access | Times Cited: 52
Page 1 - Next Page

Scroll to top